Interestingly, esophageal, lung, and ovarian tumors display both loss and gain of MPZL3. Approximately 30% of ovarian adenocarcinoma samples have MPZL3 heterozygous loss, whereas 25% exhibit chromosomal gain (Supplementary Fig. S1A), and these CNAs correlate with MPZL3 mRNA transcript levels (Fig. 1B). This evidence concerns the gene MPZL3 and ovarian neoplasm.